MyFinsight
Home
Blog
About
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,509,864
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Stock-based compensation expense
Proceeds from exercise of common...
Negative Cash Flow Breakdown
Accrued expenses
Accounts payable
Prepaid expenses and other curre...
Change in fair value of warrants
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-14,820,816
-17,606,382
-9,834,412
-7,262,658
Stock-based compensation expense
1,608,655
182,823
356,524
444,647
Change in fair value of warrants
-986,000
-268,000
296,000
-20,000
Prepaid expenses and other current assets
1,283,524
475,335
-353,275
-2,421,723
Accounts payable
-1,948,530
2,685,152
478,490
1,137,715
Accrued expenses
-4,483,405
6,470,118
-576,912
-209,042
Net cash used in operating activities
-21,913,620
-9,011,624
-8,927,035
-3,487,615
Proceeds from issuance of common stock, warrants, and pre-funded warrants, net
-
-
34,598,126
-
Proceeds from issuance of common stock, and warrants, net
26,407,199
3,698,367
-
-
Proceeds from issuance of common stock, net
-
-
-
1,643,728
Proceeds from exercise of common stock options
16,285
-
1,999
-
Net cash provided by financing activities
26,423,484
3,698,367
13,172,974
1,643,728
Net (decrease) increase in cash and cash equivalents
4,509,864
-5,313,257
4,245,939
-1,843,887
Cash and cash equivalents, beginning of period
14,219,081
19,532,338
15,286,399
10,551,916
Cash and cash equivalents, end of period
18,728,945
14,219,081
19,532,338
15,286,399
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock, and...
$26,407,199
Proceeds from exercise of
common stock options
$16,285
Net cash provided by
financing activities
$26,423,484
(33.56%↑ Y/Y)
Net (decrease)
increase in cash and cash...
$4,509,864
(-31.44%↓ Y/Y)
Canceled cashflow
$21,913,620
Stock-based compensation
expense
$1,608,655
(61.43%↑ Y/Y)
Net cash used in
operating activities
-$21,913,620
(-65.95%↓ Y/Y)
Canceled cashflow
$1,608,655
Net loss
-$14,820,816
(-26.06%↓ Y/Y)
Accrued expenses
-$4,483,405
(-1852.70%↓ Y/Y)
Accounts payable
-$1,948,530
(-46.32%↓ Y/Y)
Prepaid expenses and
other current assets
$1,283,524
(35.03%↑ Y/Y)
Change in fair value of
warrants
-$986,000
(-135.89%↓ Y/Y)
Buy us a coffee